Rona Therapeutics raised $35 Million in Series A+ financing led by LongRiver Investments

Jul 19, 2024•about 1 year ago

Amount Raised

$35 Million

Round Type

series a

ShanghaiBiotechnologyScience And Engineering

Investors

Lilly Asia VenturesZhongqi CapitalBio Track CapitalZhaode InvestmentLong River Investments

Description

Rona Therapeutics, a clinical stage pioneering platform company in nucleic acid drug research and development, completed a $35 Million Series A+ financing. LongRiver Investments led the round, with participation from investors including Zhaode Investment, BioTrack Capital, Zhongqi Capital, and Lilly Asia Ventures.

Company Information

Company

Rona Therapeutics

Location

Shanghai, Shanghai, China

About

Rona Therapeutics is a pioneering RNA therapeutics platform company dedicated to discovery and development of modular and programmable RNA medicines to deliver to patients around the world. The company is founded by industry veteran with deep expertise in RNA therapeutics program execution and world leading scientific advisors with rigorous biology understanding in the RNA space.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends